Two-loop power spectrum with full time- and scale-dependence and EFT corrections: impact of massive neutrinos and going beyond EdS
Abstract
We compute the density and velocity power spectra at next-to-next-to-leading order taking into account the effect of time- and scale-dependent growth of massive neutrino perturbations as well as the departure from Einstein--de-Sitter (EdS) dynamics at late times non-linearly. We determine the impact of these effects by comparing to the commonly adopted approximate treatment where they are not included. For the bare cold dark matter (CDM)+baryon spectrum, we find percent deviations for $k\gtrsim 0.17h~\mathrm{Mpc}^{-1}$, mainly due to the departure from EdS. For the velocity and cross power spectrum the main difference arises due to time- and scale-dependence in presence of massive neutrinos yielding percent deviation above $k\simeq 0.08, 0.13, 0.16h~\mathrm{Mpc}^{-1}$ for $\sum m_ν = 0.4, 0.2, 0.1~\mathrm{eV}$, respectively. We use an effective field theory (EFT) framework at two-loop valid for wavenumbers $k \gg k_{\mathrm{FS}}$, where $k_{\mathrm{FS}}$ is the neutrino free-streaming scale. Comparing to Quijote N-body simulations, we find that for the CDM+baryon density power spectrum the effect of neutrino perturbations and exact time-dependent dynamics at late times can be accounted for by a shift in the one-loop EFT counterterm, $Δ\barγ_1 \simeq - 0.2~\mathrm{Mpc}^2/h^2$. We find percent agreement between the perturbative and N-body results up to $k\lesssim 0.12h~\mathrm{Mpc}^{-1}$ and $k\lesssim 0.16h~\mathrm{Mpc}^{-1}$ at one- and two-loop order, respectively, for all…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.